They are divided into first-generation inhibitors, which target the PRMT5 protein but result in adverse side effects like anemia and thrombocytopenia, and second-generation inhibitors that target the PRMT5-MTA complex which do not cause any severe side effects [14]. The gene discussed is PRMT5; the disease is Thrombocytopenia.